patent map

8/11/2019 Patent Map

1/22

non-Diagnostic

AntibodiesPatent Map

[email protected]/pub/werner-deichmann-juan/33/674/526/


2/22

2

Index

Subject Page

Introduction 3

IPC classification network 4

Interpretation of the network 4

Antibody technologies. Patenting trends 6

Most prolific companies by technological classification.

Most relevant patents by company. Tag clouds 8

R&D and Patenting Opportunities (White space study) 16

Patents pointing to other possible antibody uses 18


3/22

3

Introduction

Rationale of the Patent landscapeThepresentlandscapeillustratesthedifferenttechnologicaltrendsleadingthefiledofnondiagnosticantibodies.ThetechnologicalfieldsdescribedarethosecorrespondingtotheIPCcodeunder

whichthepatentsareclassified.

Assessment of future trendsWhenconsideringthetrendsinwhichantibodyapplicationsmightdevelopeoneofthebestpossibleoptionsistofollowtheexampleofAlanTuringwhen,inordertoimaginehowcomputingmightevolve,hedescribedbackinthe1930'swhatacomputerwithinfinitememoryandcomputingpowercoulddodefinig,thatway,theprinciplesofArtificialIntelligence.Ifoneimaginewhatcouldbedoneifproducingantibodies(alsoscFv,sdAbotherkindofnanobodiesorevenaptamers)wascheapandthemethodsalmostperfectlyreliable,

theapplicationsthatantibodieswouldhaveare,verypossibly,thetrendsinwhichtheindustrywillevolve.Therewillbe,ofcourse,intheforeseablefuture,limitationsliketheneedofusingnanotechnologicaltoolsthatwillkeephavinganimpactinthepriceandoutputcapabilities.Thoselimitationsbeingconsidered,theimaginationofthementionedutopyshouldgoasfaraspossibletopreviewtheevolutionofthementionedtrends.

DisclaimerThepresentpatentlandscapehasbeenellaboratedtoaidtheR&Dteamintheassessmentofthepatentingandcommercialpossibilitiesofapotentialproduct.A

scientificteamthatisworkingonaproductthatcanbepositionedinacrowdedpatentingfieldwillhavefewerpossibilitiesofissuingapatentwithbroadclaimsandwillveryprobablyhavetofacemorecompetencefromotherproductsinthemarket.Iftheproduct,ontheotherhand,findsitselfinafieldfarremovedfromthecrowdedpatentingareasthepossibilityofissuingapatentwithbroadclaimsortheproductbeingacommercialbreakthrougharemuchhigher.Atlast,thereaderofthispatentlandscapeshouldnotconsideronlywhatisknowup-todatewhendecidingtheR&Ddirectiontotakebutconsiderhowtheentirefieldcouldevolveinthenearfuture.

Non diagnostic antibodies (Search Methodology)ThepatentsexaminedwereobtainedfromtheGlobalPatent IndexpatentsearchenginethatcontainsalltheworldregistersavailabletoEPO,usingsearchcriteriadesigned to obtain patents concerning therapeutic antibodies, mostly unrelated todiagnosis.Thesearchgaveup57765documents(20ofMay2014)

WORD=(antibod*AND(target*ORtherap*ORimmunothera*ORimmunoconju*ORautoim*ORcancer*ORtumo*ORneopla*ORleuke*orbloodORderma*ORrheuma*ORarthr*ORdiseas*)ANDNOT(diagno*ORELISAORscreen*))ANDPRD>20010101

Tag CloudsTheabstractsofthepatentdocumentsareanalyzed,termfrequenciesarecomputedandacolorisassignedtoeachterm,basedontheassignedtag.FinallytheTagCloudisusedtovisualizethemostfrequentterms.ThealgorythmhasbeenadaptedfromtheKNIMEwokwflow"GeneandProteinTagCloudExample"


4/22

4

IPC classification networkIn theoppositepageaNetworkmapofthe IPC technologyclassificationcodesassignedtopatentsisshwon.PatentshaveasignedIPCcodesexplainingwhatkindoftechnologyisbeingpatented.Usually amain code is folowed by additional codes that define other possibletechnologiesunderwhichtheinventioncanbeclassified.

Whatisrepresentedinthegraphicofpage3isthecoincidences(lines)oftwocodesinonepatent,orasinthiscase,duetothelargeamountofpatentsstudied,eachlinerepresentsthattwocodescoincide,atleast,700times(apattentcanhave10,30ormoreclassifications,allofthosewiththesame4lettercodewillbecountedascoincidences,thereforealineisnot700patents)

Interpretation of the networkHeart of the network(wheremostinventionsandrelationsbetweentechnologiesarefound)Thefollowingpiereflectsthetechnologyshareofthemajorityofpatents,many,lessfrequentclassificationshavebeenleftoutwhencalculatingthefrequencies

A61K-Medicalpreparationsfortreatingdiseases,speciallycancer,tumors,targetedantibodies,humanizedantibodies,vaccines,Immunotherapy,etc.A61P-SpecifictherapeuticactivitiesC12N - Antibody compositions, conjugated antibodies, antibody-like proteins andpolypeptides,targetedantibodies,...G01N-Measuring,testing.Immunoassays,C07K-Antibody-likepeptides,antigens,bindingfactors,...C07H-NucleotidscodingantibodiesA01K-Humanizedanimals(presentinghumanantigens),animalsproducingantibodies,

chimeric,humanized,etc.,monoclonalantibodies..C07D-antibodies,antibodyconjugates,improvedantibodies,compositionsC12P-SynthesisofantibodiesC12Q-Measuringor testing thepresenceofantibodies,antigens, imaging, bloodanalysiskits.


5/22

5

Network peripheryA61JAdministrationofantibodiestopatientsC40B Use of antibody libraries in immunoassays, in elaboration of microarrays,targetinganddetectingepitopes.A01HProductionofantibodiesinPlantsA01NMedicaltreatmentsB01JProcessesthatuseantibodies(Bloodclearing,antibodypurification)A23K Anti-carcinogenic food supplements, delivery of diseases through food tolaboratoryanimals,orallydeliveredvaccines,etc.A61MClearingbloodfrompatogens,antigens,viruses,etcA61LMedicaldevicesforisolation,methodsoffixingantibodiestomedicaldevicesA61BDiagnosis,measuring,devicesintroducedintothebody

C12MApparatusesforimmunoassay,microarrayanalysis,cellseparatingdevicesB01LMedicaldevicesfordetectionofantigensinfood,blood,etc.C07CAntibodyactivatingorinhibitingcompunds,therapeuticantigens


6/22

6

Antibody technologies. Patenting trendsThefollwingpagesowhsaparallelcoordinategraphicrepresentingthepatentingtrendsofthemostusedIPCclassificationsfornon-diagnosticantibodies.The descending trend in patenting is mostly due to the time required by thepatentingprocessestoeitherpublishtheapplication,usually18monthsfromfiling,oritsmultiplicationinseveralnationalpatentsaboutto31monthsaftertheoriginal

applicationwasfiled).Thatmeansthatasweapproachtheactualdate(June2014inthecaseofthisreport)thenumberofpatentsisincreasinglyunderrepresented.Takingthatintoaccount,thefollowinggraphicshowsacleardescentoftheuseofA61Kclassifications,thatisaverygeneraldefinitionofmedicalpreparations,ariseofC07K,speciallytheC07K16familythatcodesforImmunoglobulins(Igs)andthemaintenanceinhighpositionoftheothermorespecifictechnologies.Thetechnologicalevolutionofantibodypatentssuggestatrendtoissuepatentswithnarrowerclaims.

Most prolific IPC classifications (complete code)

Theselectionofsubclassificationsismadebyeleboratingacorrelationtableofthemostusedcodes(fourlettercodeinthecolumnnames)andtheirmostfrequentassociatedclassifications.Thefirstrowisnamed0becauseoftenpatentsareclassifiedusingjustonemaincodeandnoadditionals, the following rowsshowthemostfrequentadditionalIPCcodesassociatedtothemaincodeshowascolumnname.

A61K-Medicalpreparationsfortreatingdiseases,speciallycancer,tumors,targetedantibodies,humanizedantibodies,vaccines,Immunotherapy,etc.

Themostprolificofthemaincodesis,unsurprisingly,A61K39/395Antibodies,ImmunoglobulinsandImmuneserum


7/22

7


8/22

8

Most prolific companies by technological classification.Most relevant patents by company

A61K - Medical preparationsInthefollowinglistthemostfrequenttwoIPCcodecoincidencesareillustratedwithpatentsthathavebeenselectedfirstbetweenthemostprolificapplicantsandsecondbymostcitedpatentsoftheapplicant'sportfolio(Espacentet"citingdocuments"count)

A61K 39/395 + A61P(Specific therapeutic activities) 35/00

US8088378B2,Genentech.Anti-CD79BAntibodiesandImmunoconjugatesandMethodsofUse

US201013603,GenentechAntagonistOX40antibodiesand theiruse inthe treatment of inflammatory andautoimmunediseases

US2005053602GenentechTherapyofoculardisorders

WO9219759CHUGAIPHARMACEUTICAL(Japan)

Reconstitutedhumanantibodyagainsthumaninterleukin6receptor

WO2004022597CHUGAIPHARMACEUTICAL(Japan)Anti-glypican3antibody

WO9813388CHUGAIPHARMACEUTICALAntigen-bindingmolecule capable of binding to two or more antigenmoleculesrepeatedly


9/22

9

Medical Preparations Tag Cloud


10/22

10

WO2007109052GenentechMethodsoftreatinglupususingCD4antibodies

WO2004052932NovartisNogoAbindingmoleculesandpharmaceuticalusethereof

WO2009047356NovartisCompositionsandmethodsforuseforantibodiesagainstsclerostin

KR20120107147Novartis-ChironM-CSF-specificmonoclonalantibodyandusesthereof

WO2008155365NovartisMethodsandcompositionsfortreatingallergicdiseases

WO2005058815MedarexIP-10antibodiesandtheiruses

A61K 39/395 + C07K - The Immunoglobulin coding family: Either C07K 16/24(Immunoglobulinsagainstcytokines,lymphokinesorinterferons)C07K16/28(Igsagainstreceptors,cellsurfaceantigens)orC07K16/30(Igsfromtumourcells)Genetechhasagainthehighestcount,however,almostallarecodedalsoasA61P


11/22

11

The Immunoglobulin coding family Tag Cloud


12/22

12

G01N - Measuring, testing. ImmunoassaysThefollowingtablehasbeenellaboratedbystudyingpatentswhicharecodedunderG01NanddonotcontainthecodeA61K39/395

US2008050310GenentechAntibodiesandimmunoconjugatesandusestherefor

WO2004042009Genentech

Inhibitionofil-17production

WO2004008099Genentech&HoffmannLaRocheMethods for identifying tumors that are responsive to treatment with anti-ErbB2antibodies

US7579157HoffmannLaRocheTargetedtherapeuticsbasedonengineeredproteinsfortyrosinekinasesreceptors,includingIGF-IR

WO2006066912HoffmannLaRocheDetectionofatherapeuticantibodyinanexperimentalanimal

US2006063190TripathImagingMethodsandcompositionsforevaluatingbreastcancerprognosis

WO2005095964TripathImagingMethodsandcompositionsforthedetectionofcervicaldisease


13/22

13

Measuring, testing. Immunoassays Tag Cloud


14/22

14

C12N - Antibody compositions, conjugated antibodies, antibody-like proteins andpolypeptides, targeted antibodies,...ThefollowingtablehasbeenellaboratedbystudyingpatentswhicharecodedunderC12NanddonotcontainthecodeA61K39/395

WO2004009124CytosBiotechnologyAGGHRELIN-carrierconjugates(Ghrelinisbetterknowasthe"hungerhormone"

WO2002056907CytosBiotechnologyAGMolecularantigenarraypresentingamyloidbeta

WO2006015371GenentechHumanizedanti-cmetantagonists

WO2010077634GenentechAnti-PD-L1antibodiesandtheirusetoenhanceT-cellfunction

WO2008134659ZymogeneticsIncAntagoniststoIL-17A,IL-17F,andIL-23P19andmethodsofuse

WO0200721ZymogeneticsIncCytokinereceptorzcytor17

US8557242TheScrippsResearchInstituteERBB2antibodiescomprisingmodularrecognitiondomains


15/22

15

Antibody compositions, conjugated antibodies, antibody-like proteins and polypeptides,targeted antibodiesTag Cloud


16/22

16

R&D and Patenting Opportunities (White space study)Thisstudyisdesignedtofindnewdevelopmentopportunitiesforantibodyapplications,therapeuticornotandnotdirectlyrelatedtodiagnostics.ThestrategytofindopportunitieshasbeentocomparethealreadyshownIPCnetworkfornon-diagnosticantibodieswithanIPCnewtworkofnon-diagnosticbindingnanoparticles.Thesearchperformedhadthefollowingsynthax

WORD=((micro*ORnano*ORparticleORcompoundorchemic*)AND(specif*ORexclusi*ortarget*)+1w(bind*ORunit*ORunionORjoin*))ANDNOT(diagno*ORELISAORscreen*ORantibod*ORimmunoglobu*ORimmunoconj*)

Theactualsearchgaveup5035patenddocuments.Thegreatlyinferiornumber(a9%oftheprevioussearch)obligedtolowerthenumberofrelationsexpressedbytheconnectinglinesfrom700intheoriginalgraphicto20

Comparative of the two network graphicsTheevolutionofthepatentclassificationsshowthatmostofthetechnologies

patentedarethesameasshownintheantibodiesgraphic(page7).Asitcanbeseeninthefollowingpage,bothnetworkssharealmostthesamecenterIPC's(themostfrequent),thataretheonesrelatedtoantibodies.WiththeexceptionofthetwocentricB82BandB22Fthedifferencesareintheperypheryofthenetwork.AfarconnectionbetweenC23C(Coatingmetallicmaterial)andH05B(Electricheating)hasbeenmarkedinspiteofthesmallnumberofpatentsfoundandthatthesubjectisbarelyrelatedtoantibodies,andtherelationwon'tbeanalyzedindetail.ThisstudywillanalyzethefollowingIPCclassifications


17/22

17

Network differencesB82BNanostructuresmadebyatomicormolecularmanipulationB22FMetallicpowderandarticlesmanufacturedwithitB05DApplyingfluidstosurfacesB01DSeparationprocessB03Cmagneticseparation

G06FDataprocessingH01LSemiconductordevicesG01RMeasuringelectricalormagneticvariables

ThefollowingGraphicpresentsasmallerversionoftheantibodynetworkinordertocompareittotheIPC-networkofnon-diagnosticantibodies.ThecentralpositionofidenticalIPCclassificationsisemphasized.TheIPC'sthathavebeenfoundtobeclosetothecenterinthesecondnetworkandarenotpresentintheantibodynetworkaresurroundedbycircles


18/22

18

Outstanding differences. Patents pointing to other possible antibody uses

ThepatentsrelatedtoeachIPCclassmightbemostlyrelatedtothefieldofbiotechnology,orinahighnumberinwhichcasseonlythosewitharemostcitatedwillbedescribed(Mostcited)orpoorlyrelated/insmallnumbersinwhichcasesthemostrelevantwillbedescribed(mostrelevant)

B82B Nano structures made by atomic or molecular manipulation(Mostcited)Mostlynano-particlesconjugatedtobindingmoleculesandfluorescentcompoundsormicro-arraususedfordiagnosticsordetection

US2006246524NanoparticleconjugatesConjugatecompositionsaredisclosedthatincludeaspecific-bindingmoietycovalentlycoupledtoananoparticlethroughaheterobifunctionalpolyalkyleneglycollinker.Inoneembodiment,aconjugatesisprovidedthatincludesaspecific-bindingmoietyandafluorescentnanoparticlecoupledbyaheterobifunctionalPEGlinker.

Fluorescentconjugatesaccordingtothedisclosurecanprovideexceptionallyintenseandstablesignalsforimmunohistochemicalandinsituhybridizationassaysontissuesectionsandcytologysamples,andenablemultiplexingofsuchassays

US2002177143Non-alloyingcoreshellnanoparticlesThepresentinventionrelatescompositecore/shellnanoparticlesandatwo-stepmethodfortheirpreparation.Thepresentinventionfurtherrelatestobiomolecule-core/shellnanoparticleconjugatesandmethodsfortheirpreparation.Theinventionalsorelatestomethodsofdetectionofbiomoleculescomprisingthebiomoleculeor

specificbindingsubstance-core/shellnanoparticleconjugates.

WO03029431NanoscalingorderingofhybridmaterialsusinggeneticallyengineeredmesoscalevirusMethodsforproducingnanocrystalsofsemiconductormaterialthathavespecificcrystallographicfeaturessuchasphaseandalignmentbyusingaself-assemblingbiologicalmoleculethathasbeenmodifiedtopossessanaminoacidoligomerthatiscapableofspecificbindingtosemi-conductormaterial.Oneformofthepresentinventionisamethodtoconstructorderednanoparticleswithintheliquidcrystaloftheself-assemblingbiologicalmolecule.

WO0244725BioanalyticalassayNanoparticlecomprisingaspecificbindingreactant,saidnanoparticlebeingusefulfordeterminingananalytetowhichanalyteorcomplexcomprisingsaidanalytesaidbindingreactantisspecific.


19/22

19

B22F Metallic powder and articles manufactured with it(mostrelevant)

WO2004003508MagneticnanomaterialsandmethodsfordetectionofbiologicalmaterialsBiologicalmaterialinasampleisreactedwithanovelfunctionalizedsuperparamagneticFe/Aunanoparticlethatspecificallybindstothebiologicalmaterial

insolutiontoproduceamagneticparticle/biologicalmaterialcomplex.Thebiologicalmaterialisdetecteduponapplicationofanexternalmagneticfieldwhichseparatesthemagneticboundcomplexfromothercomponentsofthereactionmixture

US2005064508PeptidemediatedsynthesisofmetallicandmagneticmaterialsThepresentinventionincludesmethodsforproducingmagneticnanocrystalsbyusingabiologicalmoleculethathasbeenmodifiedtopossessanaminoacidoligomerthatiscapableofspecificbindingtoamagneticmaterial.

US2005074551

EthyleneglycolmonolayerprotectednanoparticlesMetallicnanoparticlescoatedwithamixedmonolayerwithwelldefinedthicknessorlengthareprepared.Themixedmonolayercomprisesacapturecoatingcomponentusefulforthespecificcaptureofmaterialsandashieldingcoatingcomponentforeliminationofnon-specificbindingofmaterialstothecapturecomponent

US2002177143Non-alloyingcoreshellnanoparticlesThepresentinventionrelatescompositecore/shellnanoparticlesandatwo-stepmethodfortheirpreparation.Thepresentinventionfurtherrelatestobiomolecule-

core/shellnanoparticleconjugatesandmethodsfortheirpreparation.Theinventionalsorelatestomethodsofdetectionofbiomoleculescomprisingthebiomoleculeorspecificbindingsubstance-core/shellnanoparticleconjugates

B05D Applying fluids to surfaces(mostrelevant)

US7709047TargetactivatedmicrotransferAmethodofremovingatargetfromabiologicalsamplewhichinvolvesplacingatransfersurfaceincontactwiththebiologicalsample,andthenfocallyaltering

thetransfersurfacetoallowselectiveseparationofthetargetfromthebiologicalsample

WO03026590BiologicalcontrolofnanoparticlesCompositionsandmethodsforselectivebindingofaminoacidoligomerstosemiconductorandelementalcarbon-containingmaterials

US2009141376Surfaceplasmonresonancecompatiblecarbonthinfilms

SPR-compatiblesubstratesforhighdensitymicroarrayfabricationandanalysesareprovided.Novelcarbon-on-metalthinfilmsubstratearchitecturepermitstheintegrationofsurfaceplasmonresonancedetectionwithphotolithographicallyfabricatedbiomoleculearraysfortheanalysisofbiomolecularinteractions.Theutilityofthe


20/22

20

technologyisshownintheanalysisofspecificDNA-DNA,DNA-RNAandDNA-proteinbindinginteractions.ThesenewsubstratesmaybeusedtodeterminethesecondarystructureofRNAmolecules,toprobethesequence-specificbindingkineticsandaffinityofproteinsandsmallmolecules,andassubstratesforsmall-moleculecombinatorialchemistryplatformsfordrugdiscoveryapplications.

B01D Separation process(Mostrelevant.MostlyChromatography)

US2005205489PrefiltersystemforbiologicalsystemsThepresentinventionistoaprefilterforpurificationsystemssuchasaffinitychromatographycolumnsandultrafiltrationsystems.Theprefilter,positionedupstreamofthesysteminlet,reducesthepresenceofnon-specificbinding(NSB)speciesthatenterthesystem...

WO2008051985

METHODFORSEPARATIONANDIDENTIFICATIONOFBIOMOLECULESUSINGUNCONVENTIONALGELELECTROPHORESISANDDETECTIONOFSINGLENANOPARTICLEPROBESThemethodinvolvescontactingasamplewithananoparticleprobethatiscapableofspecificallybindingatargetbiomolecule.Thecomplexformedbythenanoparticletargetbiomoleculeisseparatedbyelectrophoresisusinganon-conventionalgelcomposedofasyntheticallycross-linkedpolymerandagelstabilizer.

WO2009058432SAMPLEPREPARATIONDEVICE

Asamplepreparationdeviceisdisclosed.Thesamplepreparationdeviceincludesahousingdefiningapassagewaybetweenafirstopeningandasecondopening;andasamplefilteroccupyingasectionofsaidpassageway.Thesamplefiltercontainsamonolithadsorbentthatspecificallybindstonucleicacids.

B03C Magnetic separation(Mostrelevant)

US2004086885

MagneticnanomaterialsandmethodsfordetectionofbiologicalmaterialsBiologicalmaterialinasampleisreactedwithanovelfunctionalizedsuperparamagneticFe/Aunanoparticlethatspecificallybindstothebiologicalmaterialtoproduceamagneticparticle/biologicalmaterialcomplex.Amagneticfieldseparatesthemagneticboundcomplex.

US2006141450MagnetismbasedrapidcellseparationThisinventionrelatesgenerallytothefieldof.Inparticular,theinventionprovidesprocessesandkitsforisolatingatargetcell,cellularorganelleorvirusfromasample,usinginteralia,non-orlow-specificbindingbetweenatargetcell,cellular

organelleorviruswithamagneticmicrobead.


21/22

21

G06F Data processing(Mostcited)

US2003158380Modularpeptide-basedreagentTheinventionprovidesstablepeptidebackbonesintowhichoneorinteractivedomainsmaybeincorporated.Suchinteractivedomainsmaybespecificbinding

domains,inhibitordomains,linkers,labels,solidsupports,reactivesites,catalyticsites,usefulchemicalentities,andreagents.Attachmentorincorporationofaninteractivedomainintothepeptidebackbonegeneratesapeptide-basedreagent.Theinventionalsoprovidesmethodsforgeneratinglibrariesofpeptidesthatcanbeusedasinteractivedomains

US2004171062MethodsforthedesignofmolecularscaffoldsandligandsThepresentinventionprovidesmethodsofdesigningligandsthatspecificallybindtotargetmoleculesbytestingasetofdistinctcompoundstoidentifycompoundthatbindtomemberofamolecularfamilyofinterest.Thosecompoundsthatshow

bindingactivitycanbeusedasastartingpointforliganddesign..............Co-crystalsoftheproteinandthemolecularscaffoldscanbeformedandanalyzedbyX-raycrystallographytodeterminetheorientationofthescaffoldcompoundsatthebindingsiteofthemolecule........

WO2009117510MULTI-WAVELENGTHANALYSESOFSOL-PARTICLESPECIFICBINDINGASSAYSThepresentinventiondisclosesmethodsfordetectingthepresenceofacomplexbetweenafirstreagentandasecondreagentinsolution.Inparticular,theinventionprovidesmethodsforqualitativeorquantitativedetectionofananalyte

oritsspecificbindingpartnerincomplexbiologicalsamples.Theinventionfurtherdisclosesalgorithmsusingsummaryratechangesatselectedwavelengthsintheabsorbancespectraofcolloidalmetal-labeledanalytesorspecificbindingpartnerstoidentifyintermolecularinteractionsbetweentheanalyteanditsbindingpartner

H01L Semiconductor devices (Mostcited)Thisisafieldinwhichthenumberofpatentsthatarecitedisthehighest.Almosteverypatentinthisfieldhasbeencitedatleastintenpatentswheretheusualnumbersarefrom0toaround3or4citations.However,thepatentqualityhasdecayedabruptlyafter2003.Themostprolificandsuccesfuloftheinventorsbeing

AngelaBelcher(MIT,departmentofBiologicalEngineering)US2002177143Non-alloyingcoreshellnanoparticlesThepresentinventionrelatescompositecore/shellnanoparticlesandatwo-stepmethodfortheirpreparation.Thepresentinventionfurtherrelatestobiomolecule-core/shellnanoparticleconjugatesandmethodsfortheirpreparation.Theinventionalsorelatestomethodsofdetectionofbiomoleculescomprisingthebiomoleculeorspecificbindingsubstance-core/shellnanoparticleconjugatesWO03029431Nanoscalingorderingofhybridmaterialsusinggeneticallyengineeredmesoscalevirus

Thepresentinventionincludesmethodsforproducingnanocrystalsofsemiconductormaterialthathavespecificcrystallographicfeaturessuchasphaseandalignmentbyusingaself-assemblingbiologicalmoleculethathasbeenmodifiedtopossessanaminoacidoligomerthatiscapableofspecificbindingtosemi-conductormaterial.


22/22

US2003068900Biologicalcontrolofnanoparticlenucleation,shapeandcrystalphaseThepresentinventionincludescompositionsandmethodsforselectivebindingofaminoacidoligomerstosemiconductormaterials...........

US2003178641Microfluidicplatformsforusewithspecificbindingassays,specificbindingassays

thatemploymicrofluidics,andmethodsAmicrofluidicplatformforusewithaspecificbindingassayapparatusincludesanelongate,nonlinearchannelthroughwhichasampleorsamplesolutionmayflowtobebroughtintocontactwithcapturemoleculesimmobilizedrelativetoanumberofsensingzonesonareactionsurfaceofthespecificbindingassayapparatus....

WO2004093207Mixturesofmatrixmaterialsandorganicsemiconductorscapableofemission,useofthesameandelectroniccomponentscontainingsaidmixturesTheinventionrelatestonovelmixturesconsistingofatleasttwosubstances,onesubstancebeingusedasamatrixmaterialandtheotherasamaterialwhichiscapableofemissionandcontainsatleastoneelementhavinganatomicnumberlargerthan20.Theinventionalsorelatestotheuseofsaidmixturesinorganicelectroniccomponentssuchaselectroluminescenceelementsanddisplays

G01R Measuring electrical or magnetic variables (Mostrelevant)

WO0157506HighEfiicienfymagneticsensorformagneticparticlesAmagneticsensingelementdetectsthepresenceofmagneticparticlesinabinding

assay.Themagneticsensingelementhasatleastoneplanarlayerofelectricallyconductiveferromagneticmaterialthathasaninitialstateinwhichthematerialhasacircularmagneticmomentwithin theplaneofthe layer.Themagneticsensingelementhasmoleculesofafirstspecificbindingmemberattachedtoit.Thedevicealsoincludesafluidtestmediumtowhichthemagneticsensingelementisexposedduringthecourseofabindingassay.....

US2004014106ElectricaldetectionofDNAhybridizationandspecificbindingevents

Amethodfordetectingatargetanalytehavingafirstbindingsiteandasecondbindingsite.Asubstrateisprovidedhavingatleastafirstandasecondpatternedconductor,thefirstconductorbeingseparatedfromthesecondconductor....

WO2008001266MicroelectronicdevicewithmagneticmanipulatorTheinventionrelatestoamicroelectronicdevice,particularlytoamagneticbiosensor(10)whichcomprisesamagneticfieldgenerator,e.g.abondingwire(16),extendinginasamplechamber(5)adistance(d)awayfromareactionsurface(14)ofasubstrate(15)..........

patent map

Documents